Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Presentation outline
3. Toxicogenomics - what is it? (1)
4. Toxicogenomics - what is it? (2)
5. Toxicogenomics - what is it not?
6. Toxicogenomics - general considerations
7. Impact to screening and lead optimization
8. Compound discrimination: consider via dose
9. Discrimination for compounds/doses
10. Molecules discrimination requires reproducibility
11. Matched similarity of benchmark and compound
12. Correlation with "informative" signatures
13. Pathway analysis of increased genes
14. Pathway modeling
15. Modulation of the notch pathway
16. Change in notch pathway genes after treatment
17. Number of altered transcripts as an index
18. Value of overall detection of transcript changes
19. Understanding compound mechanism of action
20. Case study
21. 4-day rat studies: induced ALT and AST levels
22. Differential regulation across compounds
23. 28 gene signature correlates with toxicity
24. Clinical candidate indicated on ALT/AST chart
25. 28 gene signature of clinical candidate
26. Future candidate selection
27. For the future: translation
28. Conclusions
29. Acknowledgements

Topics Covered

• What is toxicogenomics and what is it not?
• General considerations
• Compound discrimination
• Pathway modeling
• Modulation of the notch pathway
• Altered transcripts
• Understand compound mechanism of action
• Case study: hepatotoxicity
• For the future: translation

Links

Series:

• Non-Clinical Testing for Toxicity of Pharmaceuticals

Categories:

• Pharmaceutical Sciences

Talk Citation

Afshari, C. (2009, August 9). Introduction to toxicogenomics and example case studies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/QWHS3994.
Export Citation (RIS)

Publication History

• Published on August 9, 2009

Financial Disclosures

• Dr. Cindy Afshari has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.